Wednesday, February 24 th, 2016

Transcription

1

2 List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University Hospital in Prague, Charles University. Prague, The Czech Republic Robert L. Coleman, Nicoletta Colombo, Istituto Europeo di Oncologia. Milan, Italy Luis M. Chiva, Ben Davidson, The Norwegian Radium Hospital. Oslo, Norway Andreas du Bois, Kliniken Essen Mitte. Essen, Germany Pedro F. Escobar, Instituto Gyneco-Oncológico. San Juan, Puerto Rico Anna Fagotti, Catholic University of the Sacred Heart. Rome, Italy Michael M. Frumovitz, David M. Gershenson, Antonio González-Martín, Anuja Jhingran, Matías Jurado, Clínica Universidad de Navarra. Pamplona, Spain Jonathan A. Ledermann, UCL Cancer Institute, University College. London, United Kingdom Mario M. Leitao, Memorial Sloan Kettering Cancer Center. New York, USA Karen H. Lu, Andrea Mariani, Mayo Clinic, Rochester. Minnesota, USA Christian Marth, Medical University Innsbruck, Austria Sergio Martínez, Hospital Clínic Universitari. Barcelona, Spain Ignacio Melero, Clínica Universidad de Navarra. Pamplona, Spain Mansoor R. Mirza, Rigshospitalet, Copenhagen University Hospital. Copenhagen, Denmark Gema Moreno, Ana Oaknin, Hospital General Vall d Hebron. Barcelona, Spain José Palacios, Hospital Universitario Ramón y Cajal. Madrid, Spain Sandro Pignata, National Cancer Institute Fondazione Pascale. Naples, Italy Jordi Ponce, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat. Barcelona, Spain Andrés Poveda, Fundación Instituto Valenciano de Oncología. Valencia, Spain Eric Pujade-Lauraine, Hôpital Hôtel-Dieu. Paris, France Denis Querleu, Institut Bergonié. Bordeaux, France Pedro T. Ramirez, Andrés Redondo, Hospital Universitario La Paz. Madrid, Spain Ignacio Romero, Fundación Instituto Valenciano de Oncología. Valencia, Spain Anil Sood, Gemma Toledo, Ate Van der Zee, University Medical Center of Groningen, Netherlands

3 12:00 12:15 WELCOME REMARKS Dr. Pedro T. Ramirez Dr. Antonio González-Martín Moderators: DEALING WITH RARE OVARIAN TUMORS Dr. Antonio González-Martín 12:15-12:35 Updates on novel therapies for rare tumors: From chemotherapy to innovative therapies Dr. David Gershenson 12:35-12:55 Overview of histopathologic classifications of rare tumors Dr. Gemma Toledo 12:55-13:20 Discussion 13:20-15:00 Lunch Wednesday, February 24 th, :00-15:20 KEYNOTE LECTURE Hereditary cancer genetics in the era of targeted therapies Dr. Karen H. Lu Professor and Chair H.E.B. Professorship in Cancer Research Department Gynecologic Oncology & Reproductive Medicine 15:20-15:30 Discussion 15:30-16:00 INAUGURATION BY AUTHORITIES

4 Wednesday, February 24 th, 2016 FROM LABORATORY MEDICINE TO INNOVATIVE CLINICAL APPLICATIONS: FOSTERING INNOVATION IN CONVERTING RESEARCH DISCOVERIES TO CLINICAL IMPACT Moderators: Dr. Gema Moreno Dr. José Palacios Hospital Universitario Ramón y Cajal. Madrid, Spain Dr. Ignacio Romero Fundación Instituto Valenciano de Oncología. Valencia, Spain 16:00-16:20 Intra-tumor heterogeneity: Biological and clinical implications Dr. José Palacios Hospital Universitario Ramón y Cajal. Madrid, Spain 16:20-16:40 Gene panel testing in gynecological cancer: From the lab to the clinical practice Dr. Gema Moreno 16:40-17:00 Clinical implications of molecular analysis of serous effusions in ovarian cancer Dr. Ben Davidson The Norwegian Radium Hospital. Oslo, Norway 17:00-17:15 Discussion 17:15-17:45 Coffee break 17:45-18:05 Immunostimulatory monoclonal antibodies changing the landscape of gyn-cancer treatment Dr. Ignacio Melero Clínica Universidad de Navarra. Pamplona, Spain 18:05-18:25 Targeting angiogenesis in ovarian cancer: Overcoming adaptive responses Dr. Anil Sood 18:25-18:45 Harnessing homologous recombination deficiency for specialized treatment of ovarian cancer patients Dr. Robert L. Coleman 18:45-19:00 Discussion

5 Moderators: INDIVIDUALIZING THERAPY IN ADVANCED OVARIAN CANCER Dr. Andreas du Bois Kliniken Essen Mitte. Essen, Germany Dr. Antonio González-Martín Dr. Sergio Martínez Hospital Clínic Universitari. Barcelona, Spain 08:30-08:50 Assessment of quality in ovarian cancer surgery: The ESGO perspective Dr. Denis Querleu Institut Bergonié. Bordeaux, France 08:50-09:10 Laparoscopic evaluation to assess cytoreduction Dr. Anna Fagotti Catholic University of the Sacred Heart. Rome, Italy 09:10-09:30 Clinical and radiologic assessment of feasibility of cytoreduction Dr. Giovanni Aletti Istituto Europeo di Oncologia. Milan, Italy 09:30-09:50 Predictors of residual disease in patients with ovarian cancer Dr. Anil Sood Thursday, February 25 th, :50-10:10 Adjuvant therapy in advanced ovarian cancer: Moving beyond carboplatin and paclitaxel Dr. Christian Marth Medical University Innsbruck, Austria 10:10-10:40 Discussion 10:40-11:00 Coffee break

6 Moderators: INTEGRATING RECENT ADVANCES INTO OPTIMIZING TREATMENT FOR WOMEN WITH RECURRENT OVARIAN CANCER Dr. Andrés Poveda Fundación Instituto Valenciano de Oncología. Valencia, Spain Dr. Robert L. Coleman Thursday, February 25 th, :00-11:20 Selecting the really ideal patient for secondary cytoreduction Dr. Andreas du Bois Kliniken Essen Mitte. Essen, Germany 11:20-11:40 Chemotherapy in the recurrent ovarian cancer setting: Relying on the old standard or is novel therapy the new standard? Dr. Sandro Pignata National Cancer Institute Fondazione Pascale. Naples, Italy 11:40-12:00 Critical review of PARPi s in ovarian cancer therapy: How are we going to use them and when? Dr. Jonathan A. Ledermann UCL Cancer Institute, University College. London, United Kingdom 12:00-12:20 Integrating biological therapies in recurrent disease: Looking for the perfect algorithm Dr. Eric Pujade-Lauraine Hôpital Hôtel-Dieu. Paris, France 12:20-12:40 Endpoints in ovarian cancer trials: Insights from the 2015 SGO/ASCO/AACR FDA endpoints workshop Dr. Robert L. Coleman 12:40-13:10 Discussion 13:10-14:40 Lunch

7 SENTINEL LYMPH NODE IN GYNECOLOGIC ONCOLOGY: A TIME TO SET NEW STANDARD OF CARE Moderators: Dr. Jordi Ponce Hospital Universitari de Bellvitge, L Hospitalet de Llobregat. Barcelona, Spain Dr. Michael M. Frumovitz Dr. Pedro F. Escobar Instituto Gyneco-Oncológico. San Juan, Puerto Rico 14:40-15:00 Cervical cancer: Can we stop performing complete lymphadenectomy? Dr. David Cibula General University Hospital in Prague, Charles University. Prague, The Czech Republic 15:00-15:40 Endometrial cancer: Memorial Sloan-Kettering vs. Mayo Clinic Dr. Nadeem R. Abu-Rustum Memorial Sloan Kettering Cancer Center. New York, USA Dr. Andrea Mariani Mayo Clinic, Rochester. Minnesota, USA 15:40-16:00 Vulvar cancer: Updates on current data and future trials Dr. Ate Van der Zee University Medical Center of Groningen, Netherlands Thursday, February 25 th, :00-16:20 Discussion 16:20-16:40 Personalizing targeted therapy in advanced/metastatic cervical cancer: The challenge of anti-angiogenesis therapy Dr. Ana Oaknin Hospital General Vall d Hebron. Barcelona, Spain 16:40-16:50 Discussion 16:50-17:10 Coffee break

8 Moderators: UPDATES ON THE MANAGEMENT OF ENDOMETRIAL CANCER Dr. Natalia Carballo Dr. Andrés Redondo Hospital Universitario La Paz. Madrid, Spain Dr. Matías Jurado Clínica Universidad de Navarra. Pamplona, Spain Thursday, February 25 th, :10-17:30 Current and future clinical trials in advanced/recurrent endometrial cancer Dr. Mansoor R. Mirza Rigshospitalet, Copenhagen University Hospital. Copenhagen, Denmark 17:30-17:50 Updates on standard care and novel approaches for radiation oncology in uterine cancer Dr. Anuja Jhingran 17:50-18:10 Reaching a consensus in endometrial cancer: European guidelines (ESGO-ESTRO-ESMO) Dr. Nicoletta Colombo Istituto Europeo di Oncologia. Milan, Italy 18:10-18:30 Discussion

9 Moderator: PERSONALIZED MEDICINE IN GYNECOLOGIC ONCOLOGY: LOOKING BEYOND STANDARDS Dr. Karen H. Lu 08:30-08:45 Influence of life style and psychological support in gynecologic oncology Dr. Antonio González-Martín 08:45-09:00 Targeting stress neuroendocrine pathways in cancer Dr. Anil Sood 09:00-09:15 Enhance recovery after surgery (ERAS) Dr. Pedro T. Ramirez 09:15-09:30 Discussion 09:30-09:45 SGO ANNUAL MEETING INVITATION Dr. Robert L. Coleman Friday, February 26 th, :45-10:45 TUMOR BOARD Moderators: Dr. Pedro T. Ramirez Dr. Antonio González-Martín Panel: Dr. David Gershenson Dr. Karen H. Lu Dr. Nadeem R. Abu-Rustum Dr. Andreas du Bois Dr. Nicoletta Colombo Dr. Anuja Jhingran Dr. José Palacios Dr. Pedro F. Escobar

10 10:45-11:15 MD ANDERSON SPAIN FOUNDATION AWARDS A life devoted to a great endeavour: Gynecologic oncology Dr. Andreas du Bois Kliniken Essen Mitte. Essen, Germany 11:15-11:45 Coffee break Friday, February 26 th, 2016 Moderators: INNOVATIONS IN MINIMALLY INVASIVE SURGERY Dr. Pedro T. Ramirez Dr. Michael M. Frumovitz 11:45-12:05 Update on robotic surgery in gynecologic oncology Dr. Mario M. Leitao Memorial Sloan Kettering Cancer Center. New York, USA 12:05-12:25 Role of single-port surgery by laparoscopy or robotics: Surgical innovation or a procedure without a future? Dr. Pedro F. Escobar Instituto Gyneco-Oncológico. San Juan, Puerto Rico 12:25-12:45 Discussion 12:45-13:45 SURGICAL FILM FESTIVAL Moderators: Dr. Mario M. Leitao Memorial Sloan Kettering Cancer Center. New York, USA Dr. David Cibula General University Hospital in Prague, Charles University. Prague, The Czech Republic 13:45-13:55 CLOSING REMARKS Dr. Antonio González-Martín Dr. Pedro T. Ramirez

11 Local Committee: Sonsoles Alonso Marisa Argente Elsa Bernal Raquel Bratos Natalia Carballo Teresa Castellanos Luis M. Chiva Virginia Corraliza Marta de la Fuente Irene Fernández Juan Fernando García Javier García Prado Antonio González-Martín Luis Granados Fernando Lapuente Pilar López Mendo Raúl Márquez Mar Mendivil Gema Moreno Mª Jesús Pablos Gemma Toledo Covadonga Vidal

12